Dr. Ruoxi Zhang | Cardiology | Best Researcher Award

Researcher, Harbin Medical University, China

Dr. Ruoxi Zhang is a distinguished clinical researcher and physician, currently serving as a Senior Medical Science Liaison at Hutchmed (China) Limited. With a strong foundation in clinical medicine and internal medicine from Harbin Medical University, she has built a dynamic career in both hospital and research settings. Dr. Zhang’s work spans neurobiology, cardiovascular research, and clinical trials, with significant contributions during the COVID-19 pandemic. Recognized for her medical and research excellence, she is a Fellow of The Royal Society of Medicine and the American College of Cardiology.

Profile

Scopus Profile

Education

Dr. Ruoxi Zhang pursued her medical education with a strong focus on clinical and internal medicine. She earned her Bachelor’s in Clinical Medicine from Qiqihar Medical University, China, in 2007, which provided her with a solid foundation in medical sciences and patient care. She then advanced her expertise by obtaining a Master’s in Internal Medicine from Harbin Medical University in 2010, where she specialized in diagnosing and managing a wide range of internal diseases. Dr. Zhang continued her academic journey at Harbin Medical University, completing a Doctorate in Clinical Medicine in 2016, further honing her skills in clinical research and medical practice. Her extensive academic background has played a crucial role in shaping her professional career and contributions to the medical field.

Professional Experience

Dr. Ruoxi Zhang is a highly experienced medical professional with extensive expertise in clinical medicine and research. She is currently a Senior Medical Science Liaison at Hutchmed (China) Limited, a position she has held since November 2021. Prior to this, she was a Senior Clinical Research Manager at Keya Medical Technology Co., Ltd. from October 2020 to November 2021. Dr. Zhang also served as a Physician at The Second Affiliated Hospital of Harbin Medical University for a decade (July 2010 – October 2020) while completing a postdoctoral fellowship at the Postdoctoral Mobile Station of Neurobiology at Harbin Medical University (July 2018 – Present). Her contributions to the field were recognized during the COVID-19 pandemic, earning her the title of Outstanding Doctor of COVID-19 Epidemic Prevention in Wuhan in 2020.

Research Interst

Dr. Zhang’s research focuses on neurobiology, clinical medicine, and internal medicine. She is particularly interested in cardiovascular diseases, pathophysiology, and clinical trials for novel therapeutic interventions.

Awards and Honors

Fellow of The Royal Society of Medicine (FRSM), 2022

Fellow of the American College of Cardiology (FACC), 2021

Outstanding Doctor of COVID-19 Epidemic Prevention in Wuhan, 2020

Heilongjiang Science and Technology Award, 2020

Heilongjiang College Science and Technology Award, 2019

China Postdoctoral Science Foundation Funded, 2018

Heilongjiang Postdoctoral Science Foundation Funded, 2018

Membership of the Chinese Association of Pathophysiology, 2018

Conclusion

Dr. Ruoxi Zhang’s extensive research experience, especially in clinical and neurobiological domains, combined with her numerous awards and recognitions, make her a highly suitable candidate for the Best Researcher Award. Her proven track record in clinical practice, her significant academic accomplishments, and her contributions to medical science position her well for this accolade.

Publication Top Notes

Hou, S., Zhu, X., Zhao, Q., Zhang, R., & Wu, Q. (2024). Quantitative flow ratio-guided staged percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Heliyon, 10(20), e39335.
Citations: 0

Wang, G., Qiao, W., Xing, C., Hou, J., & Yu, B. (2023). Diagnostic Performance of 60 MHz High-Definition Intravascular Ultrasound versus Fourier Domain Optical Coherence Tomography for Identifying Plaque Rupture, Plaque Erosion, and Thrombosis in a Rabbit Model. Reviews in Cardiovascular Medicine, 24(3), A51.
Citations: 0

Ma, X., Wang, Y., Liu, Q., Hou, J., & Yu, B. (2022). Vaspin alleviates the lncRNA LEF1-AS1-induced osteogenic differentiation of vascular smooth muscle cells via the Hippo/YAP signaling pathway. Experimental Cell Research, 421(2), 113407.
Citations: 4

Qu, C., Zhao, Q., Cao, W., Luo, X., & Zhang, R. (2022). Efficacy of Non-Invasive Ventilation in Acute Coronary Syndrome Patients with Acute Systolic Heart Failure. Reviews in Cardiovascular Medicine, 23(9), 294.
Citations: 0

Qu, C., Feng, W., Zhao, Q., Zhang, R., & Qu, X. (2022). Effect of Levosimendan on Acute Decompensated Right Heart Failure in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Frontiers in Medicine, 9, 778620.
Citations: 5

Wang, G., Han, B., Zhang, R., Hou, J., & Yu, B. (2021). Corrigendum: C1q/TNF-Related Protein 9 Attenuates Atherosclerosis by Inhibiting Hyperglycemia-Induced Endothelial Cell Senescence Through the AMPKα/KLF4 Signaling Pathway. Frontiers in Pharmacology, 12, 812384.
Citations: 2

Wang, G., Han, B., Zhang, R., Hou, J., & Yu, B. (2021). C1q/TNF-Related Protein 9 Attenuates Atherosclerosis by Inhibiting Hyperglycemia-Induced Endothelial Cell Senescence Through the AMPKα/KLF4 Signaling Pathway. Frontiers in Pharmacology, 12, 758792.
Citations: 20

Ruoxi Zhang | Cardiology | Best Researcher Award

Dr. Ruoxi Zhang | Cardiology | Best Researcher Award

Education

Professional Experience

Awards and Honors

Conclusion

RECOMMENDED

Mail us